pH-Dependent Bidirectional Transport of Weakly Basic Drugs Across Caco-2 Monolayers: Implications for Drug–Drug Interactions

AbstractPurpose. The purpose of this study was to investigate the pH-dependent passive and active transport of weakly basic drugs across the human intestinal epithelium. Methods. The bidirectional pH-dependent transport of weak bases was studied in Caco-2 cell monolayers in the physiologic pH range of the gastrointestinal tract. Results. A net secretion of atenolol and metoprolol was observed when a pH gradient was applied. However, the bidirectional transport of both compounds was equal in the nongradient system. Hence, at lower apical than basolateral pH a change in passive transport caused by an imbalance in the concentration of the uncharged drug species resulted in a “false” asymmetry (efflux ratio). Furthermore, a mixture of pH-dependent passive and active efflux was found for the P-glycoprotein (P-gp, MDR1, ABCB1) substrates, talinolol and quinidine, but not for the neutral drug, digoxin. However, the clinically important digoxin-quinidine interaction depended on the presence of a pH gradient. Hence, the degree of interaction depends on the amount of quinidine available at the binding site of the P-gp. Conclusions. Active efflux of weak bases can only be accounted for when the fraction of unionized drug species is equal in all compartments because the transport is biased by a pH-dependent passive component. However, this component may take part in vivo and contribute to drug-drug interactions involving P-gp.

[1]  M Zschiesche,et al.  Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P‐glycoprotein , 2000, Clinical pharmacology and therapeutics.

[2]  I. D. de Lannoy,et al.  The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. , 1992, Biochemical and biophysical research communications.

[3]  Yoshinori Morita,et al.  MDR1 Genotype-Related Pharmacokinetics of Digoxin After Single Oral Administration in Healthy Japanese Subjects , 2001, Pharmaceutical Research.

[4]  K. Luthman,et al.  Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. , 1998, Journal of medicinal chemistry.

[5]  Roger L. Black,et al.  Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1991 .

[6]  T. Márián,et al.  Intracellular pH does not affect drug extrusion by P-glycoprotein. , 1996, Journal of photochemistry and photobiology. B, Biology.

[7]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[8]  D. Clarke,et al.  The “LSGGQ” Motif in Each Nucleotide-binding Domain of Human P-glycoprotein Is Adjacent to the Opposing Walker A Sequence* , 2002, The Journal of Biological Chemistry.

[9]  G. Klebe,et al.  Transport of Peptidomimetic Thrombin Inhibitors with a 3-Amidino-Phenylalanine Structure: Permeability and Efflux Mechanism in Monolayers of a Human Intestinal Cell Line (Caco-2) , 2001, Pharmaceutical Research.

[10]  R. Pownall,et al.  The absorption of β‐adrenoceptor antagonists in rat in‐situ small intestine; the effect of lipophilicity , 1985, The Journal of pharmacy and pharmacology.

[11]  M. Boisset,et al.  Absorption of angiotensin II antagonists in Ussing chambers, Caco-2, perfused jejunum loop and in vivo: importance of drug ionisation in the in vitro prediction of in vivo absorption. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  B. H. Stewart,et al.  Atorvastatin Coadministration May Increase Digoxin Concentrations by Inhibition of Intestinal P‐Glycoprotein‐Mediated Secretion , 2000, Journal of clinical pharmacology.

[13]  M. Kataoka,et al.  Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  J. Schellens,et al.  P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. , 1999, Pharmacological research.

[15]  W. L. Chiou,et al.  An alternative hypothesis to involvement of intestinal P-glycoprotein as the cause for digoxin oral bioavailability enhancement by talinolol. , 2001, Clinical pharmacology and therapeutics.

[16]  L. A. Christensen,et al.  pH‐Profile and regional transit times of the normal gut measured by a radiotelemetry device , 1989, Alimentary pharmacology & therapeutics.

[17]  A. Tsuji,et al.  GI absorption of beta-lactam antibiotics II: deviation from pH--partition hypothesis in penicillin absorption through in situ and in vitro lipoidal barriers. , 1978, Journal of pharmaceutical sciences.

[18]  K. Luthman,et al.  Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. , 1999, The Journal of pharmacology and experimental therapeutics.

[19]  J. Belli,et al.  Changes in intra- or extracellular pH do not mediate P-glycoprotein-dependent multidrug resistance. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T. Abe,et al.  Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* , 2002, The Journal of Biological Chemistry.

[21]  W. Kirch,et al.  Direct demonstration of small intestinal secretion and site‐dependent absorption of the β‐blocker talinolol in humans , 1996, Clinical pharmacology and therapeutics.

[22]  P. Artursson,et al.  Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.

[23]  A. Seelig,et al.  Real-time monitoring of P-glycoprotein activation in living cells. , 2002, Biochemistry.

[24]  G R Wilkinson,et al.  Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. , 1999, Circulation.

[25]  N. Holford,et al.  Pharmacokinetics of quinidine and three of its metabolites in man , 1984, Journal of Pharmacokinetics and Biopharmaceutics.

[26]  D. Clarke,et al.  Location of the Rhodamine-binding Site in the Human Multidrug Resistance P-glycoprotein* , 2002, The Journal of Biological Chemistry.

[27]  C. Joyce Drug Compendium , 1970, Nature.

[28]  D. Keppler,et al.  Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. , 2001, Molecular pharmacology.

[29]  Thomas J. Raub,et al.  Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers. , 1994, Journal of pharmaceutical sciences.

[30]  J. Nezu,et al.  Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. , 1999, The Journal of pharmacology and experimental therapeutics.

[31]  B. Brodie,et al.  The gastric secretion of drugs: a pH partition hypothesis. , 1957, The Journal of pharmacology and experimental therapeutics.

[32]  R. Oertel,et al.  Interaction of talinolol and sulfasalazine in the human gastrointestinal tract , 1992, European Journal of Clinical Pharmacology.

[33]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Hirst,et al.  Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (HCT-8 and T84) layers expressing P-glycoprotein. , 1991, British Journal of Cancer.

[35]  G. McEwan,et al.  The effect of E. coli STa enterotoxin on the absorption of weakly dissociable drugs from rat proximal jejunum in vivo , 1990, British journal of pharmacology.

[36]  Gordon L. Amidon,et al.  Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs , 2002, Pharmaceutical Research.

[37]  B. Faller,et al.  High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. , 2001, Journal of medicinal chemistry.

[38]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[39]  Thomas J. Raub,et al.  Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. , 1995, Journal of pharmaceutical sciences.

[40]  N. Ellison Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 10th Edition , 2002 .